Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)Depreciation ExpenseEBIATOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

InMed Pharmaceuticals (INM) EBIAT (2021 - 2025)

InMed Pharmaceuticals' EBIAT history spans 5 years, with the latest figure at -$2.0 million for Q4 2025.

  • For Q4 2025, EBIAT rose 21.23% year-over-year to -$2.0 million; the TTM value through Dec 2025 reached -$7.7 million, up 2.97%, while the annual FY2025 figure was -$8.2 million, 6.49% down from the prior year.
  • EBIAT reached -$2.0 million in Q4 2025 per INM's latest filing, down from -$1.7 million in the prior quarter.
  • In the past five years, EBIAT ranged from a high of -$347622.0 in Q2 2023 to a low of -$7.9 million in Q2 2022.
  • Average EBIAT over 5 years is -$2.6 million, with a median of -$2.1 million recorded in 2022.
  • Peak YoY movement for EBIAT: surged 95.58% in 2023, then crashed 464.44% in 2024.
  • A 5-year view of EBIAT shows it stood at -$4.3 million in 2021, then soared by 50.94% to -$2.1 million in 2022, then increased by 29.65% to -$1.5 million in 2023, then tumbled by 74.2% to -$2.6 million in 2024, then grew by 21.23% to -$2.0 million in 2025.
  • Per Business Quant, the three most recent readings for INM's EBIAT are -$2.0 million (Q4 2025), -$1.7 million (Q3 2025), and -$1.8 million (Q2 2025).